An executive ousting, an entire dermatology unit in freefall, a mass exodus of 950 employees, and a high-stakes EOW criminal complaint. As Emcure hits the $1.1 billion milestone, an explosive internal war threatens to rewrite the rules of domestic pharma dominance. As boardroom battles
Recent Posts
- Where Is Gyanesh Kumar Now? The Constitutional Eclipse at Nirvachan Sadan
- India’s 10 Core Economic Engines: An Empirical Breakdown of Growth, Jobs, Trade, and FDI
- The Growth Arithmetic vs. Ground Realities: India’s Macro Balance Sheet Needs More Than Sectoral Triumphalism
- India’s BRICS Chairship Delivers Consensus Amid Fractures: Practical Gains, Measured Diplomacy, and Limits of Alignment
- The 3-Paise Settlement: How India’s Financial Architecture Capitulated to Subhash Chandra’s ₹22,000-Crore Default










